Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2005
05/25/2005CN1202750C Preparation method for oyster capsule food
05/24/2005US6897349 Silver-containing compositions, devices and methods for making
05/24/2005US6897239 New use of existing pharmaceutical misoprostol antiulcer agent, has a strong local vasodilation effect on applied tissue; a synergic action with combining alprostadil
05/24/2005US6897206 Combinations for the treatment of inflammatory disorders
05/24/2005US6897205 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
05/24/2005US6897202 Spray dry products, comprising glucose, maltotriose, oligosaccharides or polysaccharides of glucose; use in foods, cosmetics, and pharmaceuticals, soluble in aqueous solvents
05/24/2005US6897200 Drug delivery a macromolecular complexes containing antitumor agent conjugated with a viral and non-viral RNA or vectors; stable, nonhydrolysis, gene therapy
05/24/2005US6897196 pH sensitive lipids based on ortho ester linkers, composition and method
05/24/2005US6896914 Method for normalizing insulin levels
05/24/2005US6896906 A spray dried powder prepared by aerosolization; superior chemical and physical stability over their solution counterparts; inhaleable powder
05/24/2005US6896904 Multilayer crosslinking porous structure; prosthetic bones, drug delivery
05/24/2005US6896902 Effervescent solid composition of matter
05/24/2005US6896901 Controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin in mammals by administering pharmaceutically acceptable effective amount of gugulipid
05/24/2005US6896899 Pharmaceutical preparations of glutathione and methods of administration thereof
05/24/2005US6896898 Analgesics; antiinflammatory agents; sustained release
05/24/2005US6896897 For cosmetic and over-the-counter drug applications
05/24/2005US6896894 Proteins stabilized with polysaccharide gums
05/24/2005US6896893 Needle-less parenteral introduction device
05/24/2005US6896888 Comprises Bacillus Calmette-Guerin (BCG) formulated with keratolytic agent (salicyclic acid) for topical application
05/24/2005US6896882 Breaking peptidoglycans in cell wall; destroying genomes
05/24/2005US6896875 Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging
05/24/2005US6896659 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
05/24/2005CA2432405C Water-free skin care formulations comprising micronized urea and method of manufacturing the same
05/24/2005CA2315408C A double capsule for the administration of active principles in multiple therapies
05/24/2005CA2268140C Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
05/24/2005CA2240161C Antifungal compositions with improved bioavailability
05/24/2005CA2216570C Self-foaming cream
05/24/2005CA2214889C Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
05/24/2005CA2170243C Novel therapeutic and dietetic uses of a brain phospholipid-based complex
05/24/2005CA2144077C Hydrogel-type sustained-release preparation
05/24/2005CA2109259C Prodrugs, their preparation and use as pharmaceuticals
05/19/2005WO2005044985A2 Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections
05/19/2005WO2005044965A1 Use of a solution comprising at least one nonionic surfactant
05/19/2005WO2005044429A2 Reagent-containing membranes and laminates and methods of their prepration
05/19/2005WO2005044366A2 System and method for transdermal vaccine delivery
05/19/2005WO2005044353A1 Powder inhaler
05/19/2005WO2005044297A1 Use of interferon-tau in medecine
05/19/2005WO2005044287A1 Disinfecting composition and methods of making and using same
05/19/2005WO2005044284A1 Compositions and uses therof
05/19/2005WO2005044280A1 Biphosphonate pharmaceutical formulations (water emulsion of lipids/phospholipids) and use thereof
05/19/2005WO2005044278A1 Myo-inositol hexaphosphate for topical use
05/19/2005WO2005044276A1 Pharmaceutical composition containing prostaglandin
05/19/2005WO2005044273A1 Controlled release delivery system for nasal applications
05/19/2005WO2005044271A1 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties
05/19/2005WO2005044262A1 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
05/19/2005WO2005044258A1 Simvastatin formulations and methods of making same
05/19/2005WO2005044257A1 Discodermolide compositions
05/19/2005WO2005044255A1 Stabilized pharmaceutical compositions
05/19/2005WO2005044246A2 Controlled release analgesic suspensions
05/19/2005WO2005044243A2 Transdermal analgesic systems having reduced abuse potential
05/19/2005WO2005044242A1 Preparations for topical application and methods of delivering an active agent to a substrate
05/19/2005WO2005044241A1 Transdermal firming serum
05/19/2005WO2005044240A2 Stable lansoprazole formulation
05/19/2005WO2005044239A2 Osmotic pump with self-retaining, fast-start membrane plug
05/19/2005WO2005044238A1 Modified release solid dosage form of amphetamine salts
05/19/2005WO2005044237A1 Pharmaceutical composition having a cationic excipient
05/19/2005WO2005044236A1 Suspension delivery system for the sustained and controlled local release of pharmaceuticals
05/19/2005WO2005044235A1 Controlled release formulation of tamsulosin hydrochloride and preparation process thereof
05/19/2005WO2005044234A2 Nanoparticulate compositions having a peptide as a surface stabilizer
05/19/2005WO2005044232A1 A controlled-release composition for topical application and a method of delivering an active agent to a substrate
05/19/2005WO2005044231A1 Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use
05/19/2005WO2005044230A2 Controlled release analgesic suspensions
05/19/2005WO2005044229A1 Dispersions and methods of preparing them
05/19/2005WO2005044228A2 Compositions comprising cyclohexylamines and aminoadamantanes
05/19/2005WO2005044227A1 Topical pharmaceutical compositions
05/19/2005WO2005044226A2 Lipid formulations for spontaneous drug encapsulation
05/19/2005WO2005044225A2 Process for production of essentially solvent-free small particles
05/19/2005WO2005044224A2 Drug delivery system based on polymer nanoshells
05/19/2005WO2005044223A1 Chewable tablet
05/19/2005WO2005044222A2 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
05/19/2005WO2005044221A2 Solid active ingredient formulation
05/19/2005WO2005044193A2 Product and process for increasing compactibility of carbohydrates
05/19/2005WO2005044187A2 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
05/19/2005WO2005044186A2 Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
05/19/2005WO2005044175A2 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
05/19/2005WO2005044174A1 Seamless capsule manufacturing method, seamless capsule manufacturing device, and seamless capsule
05/19/2005WO2005044145A1 Embolic compositions
05/19/2005WO2005044006A1 Quick dissolving agrochemical products
05/19/2005WO2005033289A3 Transfection reagents
05/19/2005WO2005032511A3 Nanoparticulate therapeutic biologically active agents
05/19/2005WO2005025501A3 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
05/19/2005WO2005020879A3 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
05/19/2005WO2005016278A3 Antibiotic product, use and formulation thereof
05/19/2005WO2005015158A9 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
05/19/2005WO2005012233A8 Meldonium salts, method of their preparation and pharmaceutical composition on their basis
05/19/2005WO2005011614A8 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
05/19/2005WO2005009410A3 Pharmaceutical compositions having a swellable coating
05/19/2005WO2005007802A3 Fibrous composite for tissue engineering
05/19/2005WO2005007105A3 Pharmaceutical compositions
05/19/2005WO2004112711A3 Oral extended-release composition
05/19/2005WO2004108792B1 Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof
05/19/2005WO2004091529B1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
05/19/2005WO2004064719A3 Synergistic compositions and methods for potentiating anti-oxidative activity
05/19/2005WO2004062626A3 Composition and method for treating age-related disorders
05/19/2005WO2004024868A3 Product and process for liquefaction of mucus or sputum
05/19/2005WO2003105767A8 Antifungal parenteral products
05/19/2005US20050107959 Screening method for evaluation of bilayer-drug interaction in liposomal compositions
05/19/2005US20050107869 Apparatus and methods for controlled substance delivery from implanted prostheses
05/19/2005US20050107772 Once administered, water passes through a rate controlling membrane and into the osmotic composition, which causes the osmotic composition to expand and expel the active agent formulation through the exit orifice at a rate that is directly proportional to the rate at water passes through the membrane
05/19/2005US20050107753 Microinfusion device
1 ... 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 ... 2991